Curated news and analysis on clinical trials, drug approvals, and medical research.
InnoCare's TYK2 inhibitor fadeucravacitinib met primary and secondary endpoints in a Phase 3 psoriasis trial, with a favorable safety profile. InnoCare plans to seek regulatory approval.
Rising Pharma Holdings Inc. recalls four lots of 5 mg cetirizine hydrochloride allergy tablets after a pharmacy tech noticed possible cross-contamination with ranitidine, posing life-threatening risks to hypersensitive individuals.
Presenters at the 2026 ICE-T Conference discussed the growing role of bispecific antibodies and CAR T-cell therapies in hematologic cancers, while a separate study found that structural instability of linkers in symmetric bispecific antibodies could pose manufacturing hurdles.
The Bundibugyo Ebola outbreak in the DRC has surpassed 3,200 cases and 1,400 deaths, becoming the fastest-spreading Ebola outbreak ever. The first-ever Bundibugyo-specific vaccine trial has begun at Oxford, while healthcare workers at the epicenter have gone on strike over unpaid wages. The WHO has declared the outbreak a global health emergency.
AstraZeneca Q2 core EPS of $2.63 beat consensus, driven by 15% oncology and 8% rare disease growth. The company maintained its 2030 $80 billion revenue target and has more than 20 Phase III readouts expected over the next 18 months.
The U.S. FDA approved Nuzolvence (zoliflodacin), a single-dose oral treatment for uncomplicated urogenital gonorrhea, based on a non-inferiority Phase 3 trial. Thailand also authorized the drug under the brand Nuzolvance, expanding access in low- and middle-income countries.
A prototype smart ring tracks multiple metabolic biomarkers in sweat, while Amazon One Medical launches Health Insights for blood biomarker analysis. Pharmacies are also using point-of-care testing to personalize supplement recommendations.
Trump’s phased tariffs on medicines spur over $400 billion in US pharma investments. Indian generic makers face a 2028 deadline to adapt.
NEXT BIOMEDICAL completed an FDA pre-submission review for Nexsphere-F under the TAP program. NexEos Bio received IND clearance to begin a Phase II/III trial of NTX-1024 for vernal keratoconjunctivitis, supported by positive early clinical data.
Ultragenyx cuts 10% of staff after setrusumab Phase III misses; VERAXA Biotech shareholders approve capital and board changes at EGM.
A newly reported antimicrobial peptide, GT-2, selectively disrupts microbial membranes while sparing mammalian cells. The peptide adopts a helical conformation in response to bacterial and fungal lipids and reduced Pseudomonas aeruginosa wound burden below the detection limit in a topical model.
In the Philippines, an estimated 7.3 million adults live with chronic hepatitis B, far above regional averages. Experts warn that complex treatment guidelines may hinder front-line clinicians from initiating care, while Thailand’s success with vaccination shows a path to elimination. Expanding screening and simplifying treatment are critical steps.
Male nurses now represent 1 in 8 U.S. registered nurses, with growth concentrated in the South where shortages are acute. Recruitment efforts and shifting job-market perceptions are attracting more men, helping to meet a projected 189,000 annual openings.
New investment models and digital twin technologies are bridging gaps in rare disease drug development, where traditional funding and trial designs fall short. Patient-led funding and family offices provide capital, while regulators accept digital evidence to accelerate therapies for the more than 7,000 rare diseases with few approved treatments.
NASA's Artemis 2 SLS rocket is undergoing a second wet dress rehearsal after an earlier leak, while astronauts suit up and prepare for life in the Orion spacecraft. The 10-day mission around the moon could launch as soon as March 6.
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
The FDA has refused to file Moderna's flu vaccine candidate mRNA-1010. The company will push forward outside the U.S. and pause its combination flu vaccine, while expressing disappointment over the decision's regulatory implications.
Institutional investors disclosed major changes to their AbbVie holdings as the stock hovers near record levels. AbbVie maintains a Moderate Buy analyst consensus with a $268.10 price target, buoyed by strong quarterly earnings and a newly declared dividend.
